Global Myasthenia Gravis Drugs Market 2017-2021

Table of Contents

PART 01: Executive summary

PART 02: Scope of the report

• Market overview
• Top-vendor offerings

PART 03: Market research methodology

• Research methodology
• Economic indicators

PART 04: Introduction

• Key market highlights
• Highlights

PART 05: Pipeline analysis

PART 06: Market landscape

• Global myasthenia gravis drugs market
• Five forces analysis

PART 07: Market segmentation by therapy area

• Anticholinesterases
• Immunosuppressants
• IVIg

PART 08: Geographical segmentation

• Myasthenia gravis drugs market in Americas
• Myasthenia gravis drugs market in EMEA
• Myasthenia gravis drugs market in APAC

PART 09: Market drivers

• Approval of novel monoclonal antibodies
• High unmet medical need
• Growing research activities for the better understanding and diagnosis of myasthenia gravis

PART 10: Impact of drivers

PART 11: Market challenges

• Presence of substitutes
• Limited availability of approved drugs
• Lack of long-term commitment

PART 12: Impact of drivers and challenges

PART 13: Market trends

• Emergence of new entrants
• Growing strategic acquisitions
• Potential treatment options

PART 14: Vendor landscape

• Competitive scenario

PART 15: Key vendor analysis

• Flamel Technologies
• F. Hoffmann-La Roche
• Grifols
• Pfizer
• Shire
• Valeant Pharmaceuticals
• Other prominent vendors

PART 16: Appendix

• List of abbreviations

PART 17: Explore Technavio